September 26, 2017

Incysus submits investigational new drug (IND) application for allogeneic gamma-Delta T Cell immunotherapy for leukemia and lymphoma

Written by
“On behalf of the company, I would like to thank our scientific advisors and all of our collaborators at the UAB who helped prepare and submit this IND."